Welcome to our dedicated page for Cocrystal Pharma news (Ticker: COCP), a resource for investors and traders seeking the latest updates and insights on Cocrystal Pharma stock.
Cocrystal Pharma, Inc. (symbol: COCP) is an innovative pharmaceutical company dedicated to discovering and developing novel antiviral therapeutics. With a primary focus on treating serious and chronic viral diseases, Cocrystal employs advanced technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. By leveraging unique nucleoside chemistry and a market-focused approach to drug discovery, the company aims to deliver small molecule therapeutics that are safe, effective, and convenient to administer.
The company has made significant strides in identifying promising preclinical stage antiviral compounds that address unmet medical needs. These include treatments for hepatitis, influenza, and norovirus infections. Among its notable projects, Cocrystal Pharma is developing CC-31244, an oral, broad-spectrum replication inhibitor known as a non-nucleoside inhibitor (NNI). This investigational drug targets the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses, showcasing the company's commitment to creating groundbreaking antiviral solutions.
Cocrystal Pharma has garnered strategic investments from major industry players such as Teva Pharmaceuticals, Opko Health (OPK), Dr. Raymond Schinazi, Brace Pharmaceutical, LLC, and The Frost Group. This backing underscores the confidence that leading pharmaceutical entities have in Cocrystal's potential and technological capabilities.
As Cocrystal Pharma continues to advance its pipeline of antiviral therapeutics, the company's innovative approach and robust partnerships position it as a significant player in the biotechnology sector. Investors and stakeholders can stay updated on the latest developments, financial reports, and strategic initiatives that propel Cocrystal Pharma forward in its mission to combat viral diseases.
For those interested in the latest updates and relevant information regarding Cocrystal Pharma and its stock performance, be sure to check the latest news and announcements below.
- ---
- ---
- ---
- ---
- ---
- ---
Cocrystal Pharma, Inc. (Nasdaq: COCP) reports first-quarter 2024 financial results and updates on its antiviral drug-development programs. Topline results expected for Phase 1 oral CDI-988 and Phase 2a influenza A study. FDA feedback on CC-42344, initiation of Phase 1 study for inhaled CC-42344 planned. Positive cash flow management, $21.8 million cash on hand.
Cocrystal Pharma, Inc. completes enrollment of a Phase 2a study for its oral antiviral candidate CC-42344, aiming to combat pandemic and seasonal influenza. The study evaluated safety, tolerability, and antiviral effects of the drug. The company received positive Pre-IND feedback from the FDA for a proposed Phase 2b study. Cocrystal plans to start a Phase 1 study in Australia for an inhaled formulation of CC-42344. Recent preclinical data indicates promising results for the drug.
FAQ
What is the current stock price of Cocrystal Pharma (COCP)?
What is the market cap of Cocrystal Pharma (COCP)?
What does Cocrystal Pharma, Inc. do?
What are Cocrystal Pharma's key areas of focus?
What is CC-31244?
What technologies does Cocrystal employ?
Who are some of Cocrystal Pharma's strategic investors?
How does Cocrystal's drug discovery approach differ from others?
What stage are Cocrystal's antiviral compounds in?
What makes Cocrystal Pharma unique?
Where can I find the latest news on Cocrystal Pharma?
What is the main goal of Cocrystal Pharma?
